ARLEAVIB Trademark
Trademark Overview
On Thursday, August 31, 2017, a trademark application was filed for ARLEAVIB with the United States Patent and Trademark Office. The USPTO has given the ARLEAVIB trademark a serial number of 87591303. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, April 4, 2025. This trademark is owned by Glaxo Group Limited. The ARLEAVIB trademark is filed in the Pharmaceutical Products category with the following description:
(Based on 44(d) Priority Application) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines
General Information
| Serial Number | 87591303 |
| Word Mark | ARLEAVIB |
| Filing Date | Thursday, August 31, 2017 |
| Status | 710 - CANCELLED - SECTION 8 |
| Status Date | Friday, April 4, 2025 |
| Registration Number | 5568538 |
| Registration Date | Tuesday, September 25, 2018 |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, July 10, 2018 |
Trademark Statements
| Goods and Services | (Based on 44(d) Priority Application) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines |
| Translation of Words in Mark | The wording "ARLEAVIB" has no meaning in a foreign language. |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 2 - Sec. 8 - Entire Registration |
| Class Status Date | Friday, April 4, 2025 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Glaxo Group Limited |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | Stevenage SG12NY
GB |
| Party Name | Glaxo Group Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | Brentford, Middlesex TW89GS |
| Party Name | Glaxo Group Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Brentford, Middlesex TW89GS |
Trademark Events
| Event Date | Event Description |
| Monday, September 4, 2017 | NEW APPLICATION ENTERED |
| Friday, September 8, 2017 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, November 30, 2017 | ASSIGNED TO EXAMINER |
| Friday, December 1, 2017 | NON-FINAL ACTION WRITTEN |
| Friday, December 1, 2017 | NON-FINAL ACTION E-MAILED |
| Friday, December 1, 2017 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, May 24, 2018 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, June 6, 2018 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, May 31, 2018 | ASSIGNED TO LIE |
| Wednesday, June 6, 2018 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, June 6, 2018 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, June 7, 2018 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Wednesday, June 20, 2018 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, July 10, 2018 | PUBLISHED FOR OPPOSITION |
| Tuesday, July 10, 2018 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, September 25, 2018 | REGISTERED-PRINCIPAL REGISTER |
| Friday, October 28, 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Friday, October 28, 2022 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Friday, October 28, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Friday, August 11, 2023 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Friday, August 11, 2023 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Friday, August 11, 2023 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Friday, August 11, 2023 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Friday, August 11, 2023 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Monday, September 25, 2023 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |
| Friday, April 4, 2025 | CANCELLED SEC. 8 (6-YR) |
